Itau Unibanco Holding S.A.’s Ultragenyx Pharmaceutical RARE Stock Holding History

Itau Unibanco Holding S.A.’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-168	Closed	-$6.91K	–	408
2024 Q2	$6.91K	Buy	+168	New	+$7.17K	﹤0.01%	299
2024 Q1	–	Sell	-271	Closed	-$13K	–	307
2023 Q4	$13K	Sell	271 -59	-18%	-$2.29K	﹤0.01%	302
2023 Q3	$11.8K	Hold	330	–	–	﹤0.01%	410
2023 Q2	$15.2K	Sell	330 -17	-5%	-$789	﹤0.01%	439
2023 Q1	$13.9K	Hold	347	–	–	﹤0.01%	429
2022 Q4	$16.1K	Sell	347 -24	-6%	-$944	﹤0.01%	416
2022 Q3	$15K	Hold	371	–	–	﹤0.01%	473
2022 Q2	$22K	Buy	371 +233	+169%	+$14.3K	﹤0.01%	384
2022 Q1	$10K	Buy	138 +5	+4%	+$348	﹤0.01%	433
2021 Q4	$11K	Sell	133 -176	-57%	-$14.3K	﹤0.01%	396
2021 Q3	$28K	Buy	309 +8	+3%	+$723	﹤0.01%	312
2021 Q2	$29K	Buy	+301	New	+$31.4K	﹤0.01%	266

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Itau Unibanco Holding S.A.'s RARE Position: Q3 2024 in Review

Itau Unibanco Holding S.A. sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2024, closing a stake of 168 shares — an estimated $6.91K sold.

Itau Unibanco Holding S.A. first reported a position in RARE in Q2 2021 and held it in 12 quarters. The position peaked at $29K in Q2 2021. 300 funds tracked by Wall St. Rank hold RARE as of Q3 2024.

Itau Unibanco Holding S.A. reported no remaining Ultragenyx Pharmaceutical position as of Q3 2024 after selling out during the quarter.
Itau Unibanco Holding S.A. sold 168 Ultragenyx Pharmaceutical shares in Q3 2024, an estimated $6.91K.
Itau Unibanco Holding S.A. first reported a position in Ultragenyx Pharmaceutical in Q2 2021 and held it in 12 quarters.
Itau Unibanco Holding S.A.'s Ultragenyx Pharmaceutical position peaked at $29K in Q2 2021.
300 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2024.

Based on Itau Unibanco Holding S.A.'s 13F filing for Q3 2024, filed 14 Nov 2024.